Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$59.51 +0.1%	$58.48	$42.52 ▼ $62.89	$121.42B	0.26	10.45 million shs	6.49 million shs
GRAL GRAIL	$67.19	$53.91	$29.95 ▼ $118.84	$2.88B	3.03	594,900 shs	410,686 shs
JNJ Johnson & Johnson	$234.67 +0.1%	$233.87	$149.04 ▼ $251.71	$564.11B	0.27	7.58 million shs	5.46 million shs
MRK Merck & Co., Inc.	$122.55 +0.1%	$116.05	$75.40 ▼ $125.14	$302.33B	0.18	8.53 million shs	14.75 million shs
PFE Pfizer	$25.92 +0.1%	$26.84	$22.88 ▼ $28.75	$147.62B	0.35	37.77 million shs	22.30 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	0.00%	+4.32%	+1.25%	-2.84%	+26.93%
GRAL GRAIL	0.00%	+12.64%	+23.47%	+56.15%	+67.22%
JNJ Johnson & Johnson	0.00%	+3.47%	+3.17%	-4.42%	+53.26%
MRK Merck & Co., Inc.	0.00%	+10.05%	+9.58%	-0.87%	+57.94%
PFE Pfizer	0.00%	+2.41%	-4.03%	-4.13%	+11.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$59.51 +0.1%	$58.48	$42.52 ▼ $62.89	$121.42B	0.26	10.45 million shs	6.49 million shs
GRAL GRAIL	$67.19	$53.91	$29.95 ▼ $118.84	$2.88B	3.03	594,900 shs	410,686 shs
JNJ Johnson & Johnson	$234.67 +0.1%	$233.87	$149.04 ▼ $251.71	$564.11B	0.27	7.58 million shs	5.46 million shs
MRK Merck & Co., Inc.	$122.55 +0.1%	$116.05	$75.40 ▼ $125.14	$302.33B	0.18	8.53 million shs	14.75 million shs
PFE Pfizer	$25.92 +0.1%	$26.84	$22.88 ▼ $28.75	$147.62B	0.35	37.77 million shs	22.30 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	0.00%	+4.32%	+1.25%	-2.84%	+26.93%
GRAL GRAIL	0.00%	+12.64%	+23.47%	+56.15%	+67.22%
JNJ Johnson & Johnson	0.00%	+3.47%	+3.17%	-4.42%	+53.26%
MRK Merck & Co., Inc.	0.00%	+10.05%	+9.58%	-0.87%	+57.94%
PFE Pfizer	0.00%	+2.41%	-4.03%	-4.13%	+11.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.37	Hold	$61.31	3.04% Upside
GRAL GRAIL	2.38	Hold	$67.88	1.02% Upside
JNJ Johnson & Johnson	2.74	Moderate Buy	$253.04	7.83% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$128.18	4.59% Upside
PFE Pfizer	2.19	Hold	$28.61	10.39% Upside

Current Analyst Ratings Breakdown

Latest JNJ, BMY, PFE, MRK, and GRAL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/14/2026	PFE Pfizer	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$26.00
5/13/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform
5/13/2026	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$265.00
5/6/2026	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
5/6/2026	GRAL GRAIL	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$65.00 ➝ $69.00
5/6/2026	GRAL GRAIL	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$54.00 ➝ $56.00
5/6/2026	GRAL GRAIL	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$70.00
5/6/2026	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$125.00
5/1/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
5/1/2026	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.19B	2.52	$8.14 per share	7.31	$9.84 per share	6.05
GRAL GRAIL	$147.17M	19.59	N/A	N/A	$58.27 per share	1.15
JNJ Johnson & Johnson	$94.19B	6.00	$14.14 per share	16.60	$33.73 per share	6.96
MRK Merck & Co., Inc.	$65.01B	4.66	$11.43 per share	10.72	$18.60 per share	6.59
PFE Pfizer	$62.58B	2.36	$4.40 per share	5.89	$15.86 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$3.56	16.71	9.80	0.17	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$10.37	N/A	N/A	N/A	-253.22%	-16.42%	-14.34%	8/11/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.65	27.13	18.65	2.29	21.83%	32.60%	13.29%	7/15/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$3.55	34.52	12.53	2.76	13.59%	27.55%	10.73%	8/4/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.79	9.06	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest JNJ, BMY, PFE, MRK, and GRAL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2026	Q1 2026	GRAL GRAIL	-$2.7629	-$2.29	+$0.4729	-$2.29	$39.16 million	$40.79 million
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion
4/14/2026	Q1 2026	JNJ Johnson & Johnson	$2.68	$2.70	+$0.02	$2.14	$23.60 billion	$24.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	4.23%	+1.61%	70.79%	17 Years
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.36	2.28%	+5.25%	61.97%	64 Years
MRK Merck & Co., Inc.	$3.40	2.77%	+5.75%	95.77%	14 Years
PFE Pfizer	$1.72	6.64%	-13.20%	131.30%	16 Years

Latest JNJ, BMY, PFE, MRK, and GRAL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
4/14/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.23%	5/26/2026	5/26/2026	6/9/2026
3/2/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.23%	4/2/2026	4/2/2026	5/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.10	1.42	1.28
GRAL GRAIL	N/A	11.74	11.74
JNJ Johnson & Johnson	0.46	1.03	0.77
MRK Merck & Co., Inc.	1.02	1.30	1.06
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
GRAL GRAIL	N/A
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
GRAL GRAIL	1.83%
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.17%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
GRAL GRAIL	1,360	42.92 million	42.13 million	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

JNJ, BMY, PFE, MRK, and GRAL Headlines

Recent News About These Companies

Pfizer’s Abrocitinib Atopic Dermatitis Study Nears Data Milestone: What Investors Should Watch

1 hour ago | theglobeandmail.com

This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?

4 hours ago | fool.com

MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

May 25 at 2:28 PM | finance.yahoo.com

MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

May 25 at 1:26 PM | zacks.com

Spotting winners: Pfizer (NYSE:PFE) and branded pharmaceuticals stocks in Q1

May 25 at 9:27 AM | msn.com

Pfizer's CEO uses AI to make his biggest calls — and 64% of CEOs agree, quietly shifting your portfolio

May 25 at 7:30 AM | finance.yahoo.com

Sectoral Asset Management Inc. Sells 50,000 Shares of Pfizer Inc. $PFE

May 25 at 6:44 AM | marketbeat.com

Legal & General Group Plc Has $1.07 Billion Holdings in Pfizer Inc. $PFE

May 25 at 6:35 AM | marketbeat.com

Morningstar Investment Management LLC Cuts Stock Holdings in Pfizer Inc. $PFE

May 25 at 6:26 AM | marketbeat.com

Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%

May 25 at 6:11 AM | fool.com

Fisher Asset Management LLC Raises Position in Pfizer Inc. $PFE

May 25 at 4:34 AM | marketbeat.com

Coldstream Capital Management Inc. Acquires 113,062 Shares of Pfizer Inc. $PFE

May 25 at 3:52 AM | marketbeat.com

What's the Better Dividend Stock Today: AbbVie or Pfizer?

May 24 at 1:21 PM | fool.com

What's the Better Dividend Stock Today: AbbVie or Pfizer?

May 24 at 12:31 PM | fool.com

Swedbank AB Raises Holdings in Pfizer Inc. $PFE

May 24 at 7:01 AM | marketbeat.com

St. Louis Trust Co Takes Position in Pfizer Inc. $PFE

May 24 at 5:59 AM | marketbeat.com

Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns

May 23 at 12:32 AM | finance.yahoo.com

2 Reasons to Watch PFE and 1 to Stay Cautious

May 23 at 2:32 PM | finance.yahoo.com

Pfizer Juggles Trial Win, Setback and New Vaccine Bet

May 23 at 11:10 AM | tipranks.com

Legato Capital Management LLC Makes New $2.71 Million Investment in Pfizer Inc. $PFE

May 23 at 6:53 AM | marketbeat.com

LSV Asset Management Has $435.82 Million Stock Holdings in Pfizer Inc. $PFE

May 23 at 6:39 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ, BMY, PFE, MRK, and GRAL Company Descriptions

Bristol Myers Squibb NYSE:BMY

$59.50 +0.05 (+0.08%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$59.40 -0.11 (-0.18%)

As of 05/22/2026 07:46 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GRAIL NASDAQ:GRAL

$67.19 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$66.58 -0.61 (-0.91%)

As of 05/22/2026 07:53 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Johnson & Johnson NYSE:JNJ

$234.67 +0.33 (+0.14%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$234.43 -0.25 (-0.10%)

As of 05/22/2026 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$122.55 +0.14 (+0.11%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$122.52 -0.02 (-0.02%)

As of 05/22/2026 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$25.92 +0.02 (+0.07%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$25.91 -0.01 (-0.03%)

As of 05/22/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JNJ, BMY, PFE, MRK, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JNJ, BMY, PFE, MRK, and GRAL Earnings

Compare Dividends

Latest JNJ, BMY, PFE, MRK, and GRAL Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JNJ, BMY, PFE, MRK, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ, BMY, PFE, MRK, and GRAL Company Descriptions

Bristol Myers Squibb NYSE:BMY

GRAIL NASDAQ:GRAL

Johnson & Johnson NYSE:JNJ

Merck & Co., Inc. NYSE:MRK

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools